Matthew Elliott, MD
Neurology · Charlottesville, VANPI 1275809196
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $150 of the $174 with a category attached, or 86.3%. AstraZeneca accounts for 86.3% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for neurology clinicians in VA, where the typical reported total is $1,288.
Across 2 payments — averaging $86.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$150
- Edwards Lifesciences$24
Across 27 payments — averaging $7522.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$146K
- Biohaven Pharmaceutical Holding Company Ltd.$30K
- UCB SA$15K
- Argenx US, Inc.$12K
What the payments were for
- Speaking & faculty fees$15086%
- Food & beverage$2414%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 1 | $150 |
| Edwards Lifesciences | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIRIS$150
How this compares
$174 in reported general payments places this provider in the 25th percentile of 474 neurology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 81 | $933,206 |
| SolirisEculizumab | 13 | $653,455 |
| FirdapseAmifampridine Phosphate | 11 | $624,164 |
| Radicava OrsEdaravone | 32 | $427,006 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 50 | $395,586 |
| RelyvrioSod Phenylbutyrat/Taurursodiol | 26 | $329,831 |
| EvrysdiRisdiplam | 12 | $325,098 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 16 | $195,649 |
| Nurtec OdtRimegepant Sulfate | 21 | $37,377 |
| NuedextaDextromethorphan Hbr/Quinidine | 26 | $37,331 |
| Mycophenolate Mofetil | 190 | $36,092 |
| Pyridostigmine Bromide | 154 | $12,470 |
| Riluzole | 56 | $6,710 |
| Azathioprine | 27 | $2,783 |
| Baclofen | 110 | $2,206 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaSoliris | $150 | $653,45513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 474 neurology providers in Virginia.
Other neurology in Charlottesville
- Robert ShinCharlottesville$1.7M
- Brian WeinshenkerCharlottesville$195K
- Robert SawyerCharlottesville$55K
- Nathan FountainCharlottesville$45K
- Helen Dainton-HowardCharlottesville$41K
- Alissa HiginbothamCharlottesville$37K
- Ramsey FalconerAlexandria$2M
- Heidi CraytonVienna$1.5M
- Mark LandrioWinchester$631K
- Catherine HamRichmond$603K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.